The First FDA Warning Letter on AI: What It Means for Your Quality System

Artificial Intelligence (AI) is rapidly transforming regulated industries, from automated quality reviews and predictive maintenance to complaint handling and CAPA management.

However, with innovation comes regulatory scrutiny. The FDA's first Warning Letter involving the use of AI has become a defining moment for GMP-regulated organizations, signaling that regulators expect AI-enabled processes to be validated, controlled, monitored, and fully integrated into the organization's Quality Management System (QMS).

This webinar explores the implications of FDA enforcement actions related to AI and explains what organizations must do to maintain compliance while adopting advanced technologies. Participants will gain insight into how FDA expectations for data integrity, validation, risk management, change control, and oversight apply to AI-driven systems and decision-making processes.

The session will also discuss practical approaches for integrating AI into existing quality systems without compromising regulatory compliance. From supplier qualification and algorithm validation to human oversight and deviation management, attendees will learn how to proactively prepare for FDA inspections and avoid compliance gaps.

By understanding the regulatory landscape surrounding AI, organizations can confidently leverage innovation while maintaining patient safety, product quality, and operational excellence.

Why should you Attend:
AI adoption in regulated industries is accelerating, but many organizations remain unclear about FDA expectations regarding validation, oversight, documentation, and risk management. The FDA's first AI-related Warning Letter demonstrates that regulators are closely evaluating how companies implement and control AI-enabled systems within their quality operations.

This session provides practical guidance for understanding the compliance risks associated with AI and the steps organizations should take to ensure their quality systems remain inspection-ready.

Key Highlights:

• Regulatory Clarity: Understand the significance of the FDA's first AI-related Warning Letter and its impact on GMP-regulated industries
• Compliance Readiness: Learn how AI systems should be validated, monitored, and controlled within a compliant QMS
• Risk-Based Strategies: Discover approaches for managing AI-related risks including bias, data integrity, cybersecurity, and change management
• Practical Implementation: Gain actionable recommendations for integrating AI into quality operations while maintaining regulatory oversight

• Overview of the FDA's First AI-Related Warning Letter
• Regulatory Expectations for AI in GMP-Regulated Industries
• AI Governance and Quality System Integration
• Computer System Validation (CSV) and AI Validation Considerations
• Data Integrity and Audit Trail Requirements for AI Systems
• Managing AI Risks: Bias, Hallucinations, and Model Drift
• Change Control and Lifecycle Management for AI Applications
• Human Oversight and Accountability in AI-Assisted Processes
• AI in CAPA, Deviations, Complaints, and Risk Management
• Supplier Qualification and Third-Party AI Vendor Oversight
• Inspection Readiness and Documentation Best Practices
• Future Trends in FDA Regulation of Artificial Intelligence

• Professionals responsible for quality, compliance, validation, digital transformation, and regulatory oversight in regulated industries, including:
  • Quality Assurance Managers and Directors
  • Regulatory Affairs Professionals
  • Validation and Computer System Validation (CSV) Specialists
  • Compliance Officers
  • Manufacturing and Operations Leaders
  • IT and Digital Transformation Managers
  • CAPA and Deviation Management Teams
  • Data Integrity Specialists
  • Risk Management Professionals
  • Internal Auditors and Inspection Readiness Teams
  • Executive Leadership evaluating AI adoption strategies